US 12,083,106 B2
Methods of using a pharmaceutical composition containing pirfenidone in sustained-release tablet form
Juan Socorro Armendáriz Borunda, Mexico City (MX); José Agustín Rogelio Magaña Castro, Mexico City (MX); and Jorge Cervantes Guadarrama, Mexico City (MX)
Assigned to Excalibur Pharmaceuticals, Inc., New York, NY (US)
Filed by Excalibur Pharmaceuticals, Inc., New York, NY (US)
Filed on Jun. 17, 2021, as Appl. No. 17/351,151.
Application 16/460,407 is a division of application No. 15/831,650, filed on Dec. 5, 2017, granted, now 10,383,862.
Application 15/831,650 is a division of application No. 15/177,760, filed on Jun. 9, 2016, granted, now 9,962,374.
Application 15/177,760 is a division of application No. 14/233,600, granted, now 9,408,836, previously published as PCT/MX2012/000067, filed on Jul. 13, 2012.
Application 17/351,151 is a continuation of application No. 16/460,407, filed on Jul. 2, 2019, granted, now 11,040,030.
Claims priority of application No. MX/a/2011/007675 (MX), filed on Jul. 19, 2011.
Prior Publication US 2021/0386724 A1, Dec. 16, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4418 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 31/44 (2006.01); A61K 31/4412 (2006.01); A61K 31/717 (2006.01); A61P 25/02 (2006.01); A61P 29/00 (2006.01)
CPC A61K 31/4418 (2013.01) [A61K 9/0053 (2013.01); A61K 9/2009 (2013.01); A61K 9/2013 (2013.01); A61K 9/2054 (2013.01); A61K 9/2095 (2013.01); A61K 31/4412 (2013.01); A61P 25/02 (2018.01); A61P 29/00 (2018.01); A61K 31/44 (2013.01); A61K 31/717 (2013.01)] 20 Claims
 
1. A method for treating liver cirrhosis comprising administering to a subject in need thereof, a composition in sustained-release tablet form comprising 100 mg to 2400 mg pirfenidone, microcrystalline cellulose, low viscosity hydroxypropylmethylcellulose (HPMC), high viscosity hydroxypropylmethylcellulose (HPMC), silicon dioxide, and sodium stearyl fumarate.